Stem Cell Therapy for Blindness
Pfizer in collaboration with University College London (UCL) has developed PF 5206388, an intraocular implant consisting of a single layer of retinal pigment epithelium (RPE) cells. It consists of a polymer framework carrying stem cells, designed to be set into the eye, according to Biotecnika on August 2, 2017.
This therapy first treated a patient in 2015, however, Pfizer has recently updated the therapy. It has abandoned four of its early-stage clinical projects, including the stem cell therapy. Pfizer derived cells from the embryonic stem cells and designed them for patients with a disorder that causes blindness.
In a clinical trial conducted by the specialists at Moorfields Eye Hospital, 10 patients were to be treated of a disease called wet age-related macular degeneration (AMD). Surgeons inserted a specially engineered patch behind the retina of the patients to deliver the stem cells. The operation was successful on all the 10 participants.
PF-06282999 was created for treating acute coronary syndrome (ACS) and belonging to the myeloperoxidase (MPO) inhibitor class, which is a group known to have potential to treat a range of illnesses such as cardiovascular, inflammatory, and neurodegenerative diseases.
Sources report that Pfizer is planning to dump another applicant treating cardiovascular illnesses – monoglyceride lipase (MGLL) inhibitor PF-06818883. The inhibitor was being developed as a treatment for intracerebral hemorrhage, and glucagon receptor blocker PF-06293620 for type 2 diabetes was also discarded. Pfizer, in its second-quarter 2017 report said that it spent around US$ 3.49 billion on R&D during the first half of the year.
You may be interested
Metabolic Testing Market Key Trends, Demand, Growth, Size, Review, Share, Analysis to 2025Albert R - October 19, 2018
The Metabolic Testing Market is expected to have a highly positive outlook for the next five years 2018 – 2026 according to a recently released Metabolic Testing…
Soft Tissue Repair Market Have Rapid Growth During 2018-2026Albert R - October 19, 2018
The Soft Tissue Repair Market is expected to have a highly positive outlook for the next five years 2018 – 2026 according to a recently released Soft…
Bone Marrow Transplant Market – Increasing Prevalence Of Cancers And Anemia All Over The World Is The Major Driver For The GrowthMohit Joshi - October 19, 2018
The Bone Marrow Transplant Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released Bone Marrow Transplant Market research report. The…